ストックスクリーナーアプリを入手
0.8187
12.15%
0.0887
前日終値:
$0.73
開ける：
$0.6998
24時間の取引高:
63,466
Relative Volume:
1.48
時価総額：
$26.34M
収益：
-
当期純損益:
-
株価収益率:
-2.3519
EPS:
-0.3481
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+7.72%
1か月 パフォーマンス:
-17.88%
6か月 パフォーマンス:
-8.02%
1年 パフォーマンス:
-74.79%
1日の値動き範囲:
$0.6901
$0.8188
1週間の範囲:
$0.5714
$0.8188
52週間の値動き範囲:
$0.5714
$3.85
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
名前
Akari Therapeutics Plc Adr
セクター
電話
(646) 350-0702
住所
22 BOSTON WHARF ROAD, BOSTON
AKTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.8187 | 23.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-18 | 開始されました | Maxim Group | Buy |
| 2019-01-04 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | アップグレード | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 繰り返されました | Chardan Capital Markets | Sell |
| 2016-07-11 | 開始されました | Chardan Capital Markets | Sell |
すべてを表示
Akari Therapeutics Plc Adr (AKTX) 最新ニュース
Novel ADC Developer Akari Therapeutics to Showcase Pipeline at Major Healthcare Conference - Stock Titan
Next-Gen Cancer Drug Developer Akari Therapeutics Showcases Novel IO-Payload ADC Platform - Stock Titan
Advanced analytics toolkit walkthrough for Educational Development CorporationShare Buyback & Free Expert Approved Momentum Trade Ideas - Newser
What high frequency data says about MGTXOil Prices & Free Technical Confirmation Trade Alerts - Newser
Using AI based signals to follow BWXT2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Analyzing recovery setups for Guardian Pharmacy Services Inc. investorsMarket Volume Report & Weekly High Return Stock Forecasts - Newser
Akari Therapeutics completes $2.8 million note offering and extends warrant terms - Investing.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Cancer Drug Developer Akari Therapeutics Showcases Pipeline at Webull Biotech Conference - Stock Titan
Is BACQR still worth holding after the dipEquity Market Return Forecast Model Update - Newser
Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development - Stock Titan
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com India
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan
AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan
Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India
Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan
Oncology Deal Veteran Mark Kubik Joins Akari Therapeutics to Accelerate ADC Pipeline Growth - Stock Titan
Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan
Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks
Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India
Akari Therapeutics appoints new head of oncology business - Investing.com
Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan
Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India
Akari Therapeutics names new CEO to drive cancer drug innovation By Investing.com - Investing.com South Africa
Ibotta Inc (IBTA) Shares Soar Above 1-Year High - The News Heater
Akari Therapeutics Appoints New CEO, Current CEO to Step Down By Investing.com - Investing.com South Africa
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com
Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas
Citi reveló que Ecopetrol ha publicado la guía de sus resultados para el cuarto trimestre de 2024 - Yahoo Finanzas
Akari Therapeutics appoints new CEO and board member - Investing.com
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - Stock Titan
Riesgos y oportunidades sobre el futuro de la cotización de YPF - Yahoo Finanzas
Akari Therapeutics secures $7.6 million in private financing - Investing.com
¿Qué empresas del Ibex 35 también cotizan fuera de España? - Yahoo Finanzas
Bancolombia inicia programa para aumentar la liquidez de sus acciones - Yahoo Finanzas
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology - StockTitan
Trending UK-Based Penny Stock Picks 2024 - timothysykes.com
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
Las 100 empresas latinoamericanas que se han lanzado a conquistar Wall Street - Yahoo Finanzas
Tras filtración de datos, las acciones de Globant se hundieron 10% - Yahoo Finanzas
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
Akari Therapeutics PLC (AKTX) Stock Price, Trades & News - GuruFocus
‘Flying Whale’ Blimp That Never Lands Joins Global Airship Race - Bloomberg
Akari Therapeutics Plc Adr (AKTX) 財務データ
Akari Therapeutics Plc Adr (AKTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.40%
大文字化:
|
ボリューム (24 時間):